Bendazac
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.039.594 |
| Chemical and physical data | |
| Formula | C16H14N2O3 |
| Molar mass | 282.299 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
Bendazac (or bendazolic acid) is a nonsteroidal anti-inflammatory drug (NSAID) used for joint and muscular pain.[1]
Synthesis
Principal action is inhibition of protein denaturation.

Bendazac synthesis: BE 699226; G. Palazzo, U.S. Patent 3,470,194 (1967, 1969 both to Francesco Angelini).
Use of chloroacetamide in the alkylation step, followed by acid hydrolysis produces bendazac (instead of benzydamine).
See also
References
- ↑ Balfour JA, Clissold SP (April 1990). "Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts". Drugs. 39 (4): 575–96. doi:10.2165/00003495-199039040-00007. PMID 2190795. S2CID 46956362.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
